Archem
Commercial Invoice
ARCHEM-CI-2026-0011R
Revised Commercial Invoice — Batch Production Adjustment. This invoice revisises original proforma ARCHEM-PI-2026-0011 to reflect actual shippable quantities from batch 999001. 81 vials (2.4%) were lost during fill/lyophilization. The original total of $35,450.91 has been adjusted by $738.43 on a pro-rata basis. Deposit of $17,700.00 received in cash is credited. Goods have been manufactured and dispatched.
Supplier (Issued By)
Archem FZCO
Level 14, Boulevard Plaza Tower 1
Sheikh Mohammed Bin Rashid Boulevard, Dubai, UAE
+971 5855 88152 · info@archem.bio
Buyer (Bill To)
Hush Pharma
[Registered address]
[Contact name & email]
[Tax / business ref.]
Invoice Number
ARCHEM-CI-2026-0011R
Original PI
ARCHEM-PI-2026-0011
Issue Date
July 22, 2026
Currency
USD
Incoterms
DAP — door
# Product Ordered Shipped Short Unit (USD) Line Total (USD)
1 Reta 5mg
Retatrutide 5 mg
 300 297 -3 $3.648 $1,083.45
2 Reta 10mg
Retatrutide 10 mg
 300 298 -2 $4.835 $1,440.83
3 Reta 20mg
Retatrutide 20 mg
 300 297 -3 $7.209 $2,141.07
4 Reta 40mg
Retatrutide 40 mg
 500 497 -3 $12.948 $6,435.16
5 Reta 50mg
Retatrutide 50 mg
 500 495 -5 $16.185 $8,011.57
6 Reta 60mg
Retatrutide 60 mg
 500 488 -12 $19.422 $9,477.94
7 Tesa 10mg
Tesamorelin 10 mg
 500 474 -26 $5.779 $2,739.25
8 Tesa 5mg / Ipa 5mg
Tesamorelin 5 mg / Ipamorelin 5 mg
 500 473 -27 $7.152 $3,382.90
Original PI Total$35,450.91
Pro-rata reduction (81 vials)-$738.43
Adjusted Invoice Total $34,712.17
Deposit Received (Cash) $17,700.00
Balance Due $17,012.17
Per-vial pricing derived from original PI line totals ÷ ordered vials. Balance due upon batch completion, prior to dispatch. Payable in USDT ERC-20 to 0x03ca6882ddad63de8e4582736cef1e585ce2f2c9.
Terms & Conditions
  1. Payment — Cryptocurrency (USDT). Balance of $17,012.17 due from the Buyer, payable in USDT ERC-20 (Ethereum) to the Supplier's wallet: 0x03ca6882ddad63de8e4582736cef1e585ce2f2c9. Deposit of $17,700.00 (cash) has been received and credited.
  2. Pricing — all-inclusive. Unit prices are firm and inclusive of international freight to the destination nominated by the Buyer. No additional charges for standard packaging or courier. Customs duties / import taxes, if any, are for the Buyer's account.
  3. Quantity adjustment. This revised invoice reflects actual shippable quantities from batch 999001. A total of 81 vials (2.4%) were lost during fill, lyophilization, and packaging. Line totals have been reduced on a pro-rata basis at the per-vial rate derived from the original PI.
  4. Potency & content guarantee. Purity guaranteed at a minimum of 98% by HPLC. Net peptide content guaranteed at no less than 90% of the labeled amount. Recourse: should a delivered batch test below the guaranteed purity or content floor on independent analysis performed by one of the following approved laboratories — Janoshik Analytical, TrustPointe Analytics, or Chromate Labs — the Supplier and Buyer will agree on a remedy: (a) remake of the affected batch at no additional charge, or (b) a refund — full for purity below 98%, pro-rata for content shortfalls.
  5. Product format. Lyophilized powder, sterile vials. Tesa/Ipa supplied as a co-formulated blend (5 mg / 5 mg per kit).
  6. Customs seizure re-shipment. If a shipment is confiscated or seized by customs in transit, the Supplier will re-ship the order once at no additional charge. Limited to a single complimentary re-shipment per order.
Supplier
Archem FZCO
July 22, 2026
Buyer
Hush Pharma
Date
Archem FZCO  ·  Level 14, Boulevard Plaza Tower 1, Sheikh Mohammed Bin Rashid Boulevard, Dubai, UAE  ·  +971 5855 88152  ·  info@archem.bio
This Commercial Invoice is issued by Archem FZCO for the supply of research-grade peptide materials for research / analytical purposes. Products are not intended for human consumption, clinical use, or resale as therapeutics. Confidential — intended only for the named Buyer. This revised invoice supersedes ARCHEM-PI-2026-0011 for billing purposes.